 |
245 Diseases |  |
54 Trials |
|
54 Trials |  |
1419 News |  |
| «12345678910111213...2021» |
- AB-205 / Angiocrine
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care (SOC) Versus Placebo Plus Standard of Care in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (E-CELERATE) (NCT05181540) - Trials in Progress (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_6579;
P1, P3
Daily assessments of oral/GI SRRT will occur from start of HDT to Day +21 post AHCT (Figure 1). Current status: Active recruitment and enrollment ongoing [NCT05181540].
- Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Phase II Study of Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance in Patients with Secondary Central Nervous System Lymphoma (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_6074;
P2
The safety and tolerability of this regimen in SCNSL patients were favorable. More clinical data will be updated from this ongoing study (NCT05398224).
- melphalan / Generic mfg., fludarabine IV / Generic mfg., thiotepa / Generic mfg.
Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation – a Registry Study on Behalf of the EBMT Acute Leukemia Working Party (ENMCC - 393-396) - Nov 4, 2022 - Abstract #ASH2022ASH_5262;
Differences in GvHD prophylaxis and in melphalan dose were observed in both cohorts, which might have influenced patient outcomes. In conclusion, the addition of a second alkylating agent (BCNU/carmustine or thiotepa) to FluMel as FBM/FTM conditioning improves overall survival in AML patients with intermediate/poor risk cytogenetics in CR.
- Autologous Stem Cell Transplantation for Treatment with Curative Intent in Adult Patients with Acute Lymphoblastic Lymphoma (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4824;
The majority of patients (30/32, 94%) received induction chemotherapy on the NHL 98-01 protocol (consisting of doxorubicin, cyclophosphamide, vincristine, prednisone, and asparaginase)...Two received BEAM (carmustine, etoposide, cytarabine, melphalan); both died from disease relapse post-AutoSCT...It also offers the advantage of a shorter treatment course compared to ALL-type chemotherapy. Further research is required to make direct comparison between these two distinct therapeutic approaches and provide guidance on the best practice.
- Yescarta (axicabtagene ciloleucel) / Gilead
Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects (Hall D (Ernest N. Morial Convention Center)) - Nov 4, 2022 - Abstract #ASH2022ASH_4740;
This risk is associated with prolonged reduction in WBC, ANC, and ALC but not platelets or hemoglobin. Clinical surveillance for infections in these immune compromised CAR-treated patients therefore remains critical, with role of additional prophylaxis strategies needing further investigation.
- melphalan / Generic mfg., busulfan / Generic mfg., carmustine / Generic mfg.
Hematopoietic Stem Cell Transplantation Activity for Lymphoma: A Multicentric Study By the Transplantation and Cellular Therapy Mexican Working Group (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_3156;
For relapsed patients, autologous transplantation remains the best option, the lack of carmustine was not an obstacle for favorable outcomes. The prognosis for refractory patients was dismal independently of the type of transplant, and the use of new targeted therapies before transplantation is desirable in this population.
- Tecam (Thiotepa, Etoposide, cyclophosphamide, Cytarabine and Melphalan) Is an Effective and Safe Conditioning Regimen for Autologous Transplant in Lymphoma (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2994;
BEAM (carmustine, cytarabine, etoposide and melphalan) is the most commonly used conditioning regimen; however, due to limited availability and toxicity of carmustine, thiotepa-containing regimens have been suggested. TECAM is a safe, effective, CNS-penetrating conditioning regimen for ASCT, in HL and various NHL's.
- Hematopoietic Stem Cell Transplantation in Bangladesh : Activity and Outcome Update (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2991;
Some leukemia patients received total body irradiation( TBI), thiotepa and Fludarabine based conditioning chemotherapy...National transplant registry and national donor registry both are yet to be developed. Comparing the cost difference with developed countries the overall outcome of stem cell transplantation is not inferior in Bangladesh.
- Impact of Timing of Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2990;
Although limited by the sample size and retrospective nature, whether autoHCT for PCNSL was performed in CR1 or CR2+ did not impact OS in our analysis, but CIR was higher and PFS was lower when autoHCT was performed in CR2+. Supporting the Alliance trial, autoHCT in CR1 produced longer PFS than NMA-C and patients deemed appropriate candidates for MAC consolidation in CR1 should be considered for autoHCT in this setting.
- methotrexate IV / Generic mfg.
Consolidation Improves Survival in Primary Central Nervous System Lymphoma without Preference for Type of High-Dose Methotrexate-Based Induction Treatment Regimen (ENMCC - New Orleans Theater C) - Nov 4, 2022 - Abstract #ASH2022ASH_1534;
The current treatment strategies of PCNSL are governed by high-dose methotrexate (HD-MTX)-based (immuno)chemotherapies, and in young and fit patients combined with high-dose cytarabine (HD-AraC)...Patients receiving two other combination regimens of HD-MTX (intended =12g/m2) with procarbazine or teniposide and carmustine as standard first-line therapeutic strategy were assigned to the ‘moderate’ treatment group...Sequential consolidation with WBRT or autoSCT was significantly associated with improved OS, regardless of type of HD-MTX-based induction regimens. Disregarding assessment of toxicity, these results together with other studies call for induction therapy with HD-MTX-based (immuno)polychemotherapy irrespective of type of regimen and sequential consolidation therapy with either WBRT or autoSCT, thereby shaping next treatment algorithms.
- | carmustine / Generic mfg.
Journal: Brain targeted delivery of carmustine using chitosan coated nanoparticles via nasal route for glioblastoma treatment. (Pubmed Central) - Nov 3, 2022
The AUC of brain obtained with carmustine-loaded nanoparticles via nasal administration in Albino Wistar rats was 2.8 and 14.7 times that of intranasal carmustine suspension and intravenous carmustine, respectively. The MTT assay on U87 MG cell line showed a significant decrease (P < 0.05) in the IC50 value of the formulation (71.23 μg mL) as compared to drug suspension (90.02 μg mL).These findings suggest chitosan coated nanoparticles could be used to deliver carmustine via intranasal administration to treat Glioblastoma multiforme.
- | temozolomide / Generic mfg., carmustine / Generic mfg.
Preclinical, Journal: Hydrogel-based microfluidic device with multiplexed 3D in vitro cell culture. (Pubmed Central) - Oct 30, 2022
Hydrogels are efficiently and reproducibly loaded in all wells and cells are evenly distributed throughout the hydrogel, maintaining > 90% viability for up to 4 days. In a drug screening assay, diffusion of temozolomide and carmustine to hydrogel-encapsulated U87 cells from the perfusion solution is measured, and dose-response curves are generated, demonstrating utility as an in vitro mimic of the glioblastoma microenvironment.
- || busulfan / Generic mfg., thiotepa / Generic mfg., carmustine / Generic mfg.
Conditioning included carmustine-thiotepa (84%), busulfan-thiotepa (13%) (+ other small numbers in paper). We standardly use carmustine-thiotepa in UK (Twitter) - Oct 27, 2022
- | Journal: Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support. (Pubmed Central) - Oct 21, 2022
Sixty-six patients (69%) were bridged to new lines of therapy, including clinical trials. Non-myeloablative chemotherapy with SCB provides rapid disease control and marrow recovery with potential to receive further therapy.
- | Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
Preclinical, Journal: Protective effects of cerebrolysin against chemotherapy (carmustine) induced cognitive impairment in Albino mice. (Pubmed Central) - Oct 21, 2022
However, mice treated with CBN (44 and 88 mg/kg, i.p.) significantly and dose-dependently improved cognitive functions, reduced oxidative stress markers, inflammatory cytokines and restored neurotransmitters concentration as compared to BCNU administered mice (p < 0.05). The finding of current study suggested that CBN could be the promising compound to reverse cognitive impairment associated with use of chemotherapy.
- | bendamustine / Generic mfg.
Journal: Impact of Implementing a Bendamustine-based Conditioning Regimen on outcomes of Autologous Stem Cell Transplant in Lymphoma while Novel Cellular Therapies Emerge. (Pubmed Central) - Oct 16, 2022
The finding of current study suggested that CBN could be the promising compound to reverse cognitive impairment associated with use of chemotherapy. While novel therapies emerge, our study demonstrates that Benda-EAM is safe, effective and should be considered a valid alternative to BCNU conditioning to improve outcomes of chemosensitive r/R lymphomas undergoing ASCT.
- | Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, Trial primary completion date, IO biomarker: Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Oct 12, 2022
P3, N=302, Recruiting, Sponsor: National Cancer Institute (NCI)
While novel therapies emerge, our study demonstrates that Benda-EAM is safe, effective and should be considered a valid alternative to BCNU conditioning to improve outcomes of chemosensitive r/R lymphomas undergoing ASCT. Trial completion date: Oct 2022 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Oct 2023
- || cisplatin / Generic mfg., cyclophosphamide / Generic mfg., carmustine / Generic mfg.
Retrospective data, Review, Journal: Role of High-Dose Adjuvant Chemotherapy Followed by Autologous Stem Cell Transplantation in Locally Advanced Triple-Negative Breast Cancer: A Retrospective Chart Review. (Pubmed Central) - Oct 11, 2022
This study of locally advanced/high-risk triple-negative breast cancer treated with adjuvant high-dose chemotherapy and autologous stem cell transplant reveals high overall survival rate. With the current improvement in treatment-related mortality, re-evaluating this approach in this subset of high-risk breast cancer in prospective randomized studies may be worthwhile.
- | CMV/CD19 bi-Specific CAR T / City of Hope
Enrollment open, CAR T-Cell Therapy: Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 10, 2022
P1, N=15, Recruiting, Sponsor: City of Hope Medical Center
With the current improvement in treatment-related mortality, re-evaluating this approach in this subset of high-risk breast cancer in prospective randomized studies may be worthwhile. Not yet recruiting --> Recruiting
- ||| thiotepa / Generic mfg., carmustine / Generic mfg.
Is it plasmablastic lymphoma? typically CD20 neg, would have used Len/pom initially due to CNS activity. Now i would do cranial XRT then matrix followed by carmustine/thiotepa based auto (Twitter) - Oct 9, 2022
- | cyclophosphamide / Generic mfg., cytarabine / Generic mfg., carmustine / Generic mfg.
Trial completion, Trial completion date: AutoMS-Swe: Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden (clinicaltrials.gov) - Oct 4, 2022
P=N/A, N=175, Completed, Sponsor: Uppsala University
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Dec 2022 --> Sep 2022
- | carmustine / Generic mfg.
Preclinical, Journal: Protective role of Codiaeum variegatum against genotoxicity induced by carmustine in somatic and germ cells of male mice. (Pubmed Central) - Sep 30, 2022
The results indicated that Cr is genotoxic in both somatic and germ cells. The active components in C. variegatum together participate in the obtained protective role.
- | Epidaza (chidamide) / Chipscreen
Enrollment open: Chi-BEAM: Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma (clinicaltrials.gov) - Sep 29, 2022
P2, N=23, Recruiting, Sponsor: Ruijin Hospital
The active components in C. variegatum together participate in the obtained protective role. Not yet recruiting --> Recruiting
- || Zynyz (retifanlimab-dlwr) / Incyte
Enrollment open, Combination therapy, IO biomarker: Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma (clinicaltrials.gov) - Sep 28, 2022
P1, N=50, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
MATRix regimen for newly diagnosed primary CNS diffuse B-cell lymphoma (West/Central Hall) - Sep 28, 2022 - Abstract #SNO2022SNO_491;
Patients without disease progression received carmustine 400 mg/sq m and thiotepa 5 mg/kg followed by autologous bone marrow transplantation...These preliminary data suggest that the MATRix regimen in safe and highly effective in the newly diagnosed setting. However, the high incidence of early death in patients over 65 y suggests that the regimen may be too toxic for older individuals.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
MATRix regimen for newly diagnosed primary CNS diffuse B-cell lymphoma (West/Central Hall) - Sep 28, 2022 - Abstract #SNO2022SNO_224;
Patients without disease progression received carmustine 400 mg/sq m and thiotepa 5 mg/kg followed by autologous bone marrow transplantation...These preliminary data suggest that the MATRix regimen in safe and highly effective in the newly diagnosed setting. However, the high incidence of early death in patients over 65 y suggests that the regimen may be too toxic for older individuals.
- || Review, Journal: Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice. (Pubmed Central) - Sep 22, 2022
The most widely-used treatment was psoralen ultra-violet A (PUVA) in monotherapy or in association with other drugs...Other therapy reported were based on Brentuximab Vedotin, Mogamulizumab, Carmustine, topical steroids, tazarotene and excimer laser, interferon, nitrogen mustard, imiquimod, systemic chemotherapy, extracorporeal photopheresis and stem cell transplantation...Retinoids, although widely used, appear to be poorly effective in monotherapy, particularly acitretin...Ionizing treatments, such as radiotherapy and TSEBT, appear effective, at least in the short term. Overall, an integrated approach is mandatory for the inconstant course of the disease and its multidisciplinary nature.
- | melphalan / Generic mfg.
New trial: A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant (clinicaltrials.gov) - Sep 14, 2022
P=N/A, N=20, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- lomustine / Generic mfg.
A CASE OF LOMUSTINE-INDUCED PNEUMONITIS (Convention Center Exhibit Hall: Rapid Area 2D) - Sep 11, 2022 - Abstract #CHEST2022CHEST_3774;
Toxicities such as pneumonitis have been rarely demonstrated. Timely recognition of pneumonitis features is key to treat this complication, improve quality of life, and prevent permanent lung compromise.
- Leukeran (chlorambucil) / GSK, Matulane (procarbazine hydrochloride) / Leadiant Biosci
GONADOTOXICITY RISK EVALUATION AND REPRODUCTIVE OUTCOMES IN YOUNG ADULTS WITH SOFT TISSUE AND BONE SARCOMA TREATED WITH CHEMOTHERAPY AND/OR RADIATION THERAPY: A SINGLE CENTER RETROSPECTIVE STUDY () - Sep 9, 2022 - Abstract #CTOS2022CTOS_323;
Our data confirm the lack of a clear threshold for risk of menstrual/semen disorders, and consequent possible higher risk of infertility. Long-term fertility issues associated to the treatment for sarcoma should be discussed in all adults in fertile age, along with providing essential information on fertility preservation strategies.
- | carmustine / Generic mfg.
Journal: Ventricular opening and cerebrospinal fluid circulation accelerate the biodegradation process of carmustine wafers suggesting their immunomodulation potential in the human brain. (Pubmed Central) - Aug 31, 2022
Our study findings strongly suggest that biomaterials may possess immunomodulation capacity, which is significantly impacted by the ventricular opening procedure. Furthermore, our data highlights the pathophysiological effects of the ventricular opening within the surrounding human brain, especially after the wafer implantation.
- | Retrospective data, Journal: Comparison of CEAC, BEAM and IEAC conditioning regimens followed by autologous stem cell transplantation in peripheral T-cell lymphoma patients. (Pubmed Central) - Aug 31, 2022
In conclusion, CEAC and IEAC regimen can be used as alternative conditioning regiments for ASCT in PTCL patients, and their efficacy and safety are comparable to BEAM regiment. Patients with high PIT score and non-CR early after ASCT had worse outcomes.
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
New P1 trial: Targeting Pediatric Brain Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) (clinicaltrials.gov) - Aug 30, 2022
P1, N=20, Not yet recruiting, Sponsor: Washington University School of Medicine
- | Matulane (procarbazine hydrochloride) / Leadiant Biosci
Journal: Molecular characteristics of incidental lower-grade glioma for treatment decision-making. (Pubmed Central) - Aug 25, 2022
Patients with high PIT score and non-CR early after ASCT had worse outcomes. The new insights regarding the different molecular features of iLGG and sLGG indicated that the immediate management of iLGG could result in better prognosis than the wait-and-see strategy.
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy: Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma (clinicaltrials.gov) - Aug 16, 2022
P1, N=30, Recruiting, Sponsor: Case Comprehensive Cancer Center
The new insights regarding the different molecular features of iLGG and sLGG indicated that the immediate management of iLGG could result in better prognosis than the wait-and-see strategy. Trial completion date: Aug 2023 --> Feb 2023 | Trial primary completion date: Aug 2022 --> Dec 2022 | Suspended --> Recruiting
- | carmustine / Generic mfg.
Journal: Regulation of water access, storage, separation and release of drugs from the carbon nanotube functionalized by cytosine rich DNA fragments. (Pubmed Central) - Aug 13, 2022
We found that carmustine can be stored in the carbon nanotube (CNT) interior for a long time due to hydrophobic interactions...The latter process is likely to occur spontaneously at acidic pH when intercalation of doxorubicin within the DNA fragments becomes ineffective. The features of the proposed molecular model, obtained from molecular dynamics simulations, can be beneficial in design of novel smart drugs carriers to a tumor microenvironment revealing the reduced extracellular pH.
- || Enrollment closed: Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov) - Aug 12, 2022
P2, N=59, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
The features of the proposed molecular model, obtained from molecular dynamics simulations, can be beneficial in design of novel smart drugs carriers to a tumor microenvironment revealing the reduced extracellular pH. Recruiting --> Active, not recruiting
- | 7-Hydroxystaurosporine (UCN-01) / National Cancer Institute, Alecensa (alectinib) / Roche
Journal, IO biomarker, Pan tumor: Comprehensive Bioinformatics Analysis of Toll-Like Receptors (TLRs) in Pan-Cancer. (Pubmed Central) - Aug 10, 2022
TLR7 was significantly positively correlated with the drug sensitivity of alectinib. Our study reveals the significant role of TLRs family in pan-cancer and provides potential therapeutic strategies of cancer.
- | Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma
Trial initiation date, Combination therapy: Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Aug 5, 2022
P1, N=20, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Center
Our study reveals the significant role of TLRs family in pan-cancer and provides potential therapeutic strategies of cancer. Initiation date: Aug 2022 --> Nov 2022
- | melphalan / Generic mfg.
Journal: Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplant. (Pubmed Central) - Aug 5, 2022
Higher melphalan exposure was significantly associated with increased metabolic toxicities but did not seem to impact progression-free survival. While our study suggests a melphalan AUC of 8 mg*h/L to be a potential target in BEAM, larger prospective studies using personalized PK-directed melphalan dosing are needed to determine the optimal melphalan exposure in lymphomas.
- | Journal: Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B Cell Lymphoma. (Pubmed Central) - Aug 5, 2022
Patients ≥70 years had a higher mortality (HR 1.39, 95% CI 1.05-1.85, p=0.02), likely due to inferior post-relapse OS in this cohort (HR 1.82, 95% CI 1.27-2.61, p=0.001). DLBCL was the major cause of death in both cohorts (62% vs. 59%) : Older patients should not be denied auto-HCT solely based on chronological age.
- | carmustine / Generic mfg.
Journal, Gene Signature: Identification of a Prognostic Microenvironment-Related Gene Signature in Glioblastoma Patients Treated with Carmustine Wafers. (Pubmed Central) - Jul 29, 2022
We found different transcriptomic profiles, and we identified four genes, specifically down-regulated in GASC isolated from long-term survivors, correlated with clinical data deposited in the TCGA-GBM dataset. Our results highlight that studying the in vitro properties of patient-specific glioma microenvironments can help to identify molecular determinants potentially prognostic for patients treated with CW.
- || Retrospective data, Review, Journal: Outpatient autologous stem cell transplantation in Royal Hobart Hospital, Tasmania: a single-centre, retrospective review in the Australian setting. (Pubmed Central) - Jul 29, 2022
Our results highlight that studying the in vitro properties of patient-specific glioma microenvironments can help to identify molecular determinants potentially prognostic for patients treated with CW. Outpatient autografts may save healthcare resources without compromising patient outcomes.
- | Calquence (acalabrutinib) / AstraZeneca
Trial completion date, Trial primary completion date: Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL (clinicaltrials.gov) - Jul 23, 2022
P2, N=47, Recruiting, Sponsor: Swedish Medical Center
Outpatient autografts may save healthcare resources without compromising patient outcomes. Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Sep 2021 --> Sep 2023
- | carmustine / Generic mfg.
Journal: Cerebral Edema Due to Chemotherapeutic Wafer Implantation for Malignant Glioma: Registry Study of Correlation with Perioperative Epileptic Seizures. (Pubmed Central) - Jul 23, 2022
Factors predicting adverse events following implantation with wafers containing 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine, BCNU), which is used in local chemotherapy for malignant gliomas (MGs), are unknown...Factors predictive of postoperative seizures were WHO grade III MGs (p = 0.0026), increased postoperative CE (p = 0.0272), and history of preoperative seizures (p = 0.0316). Postoperative CE, WHO grade III MGs, and a history of preoperative seizures might predict the postoperative occurrence of seizures, necessitating stringent management of seizures and CE in the affected patients.
- | CMV/CD19 bi-Specific CAR T / City of Hope
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jul 21, 2022
P1, N=15, Not yet recruiting, Sponsor: City of Hope Medical Center
Postoperative CE, WHO grade III MGs, and a history of preoperative seizures might predict the postoperative occurrence of seizures, necessitating stringent management of seizures and CE in the affected patients. Trial completion date: Apr 2025 --> Apr 2027 | Trial primary completion date: Apr 2025 --> Apr 2026
- | Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience
New P3 trial: ChiCGB vs BEAM in High-risk or R/R Lymphomas (clinicaltrials.gov) - Jul 20, 2022
P3, N=306, Recruiting, Sponsor: Sichuan University
- || carmustine / Generic mfg.
Review: Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option? (Pubmed Central) - Jul 13, 2022
This meta-analysis seems to suggest that CWs implantation plays a significant role in improving the OS, when used in patients with newly diagnosed HGG. To minimize the risk of side effects, however, a carful patient selection based mainly on patient age and tumor volume should be desirable.
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. (Pubmed Central) - Jul 8, 2022
A second randomization allocated patients with responsive/stable disease to whole-brain irradiation (WBRT) or carmustine-thiotepa-conditioned autologous transplantation (ASCT)...Importantly, MATRix and ASCT did not result in higher non-relapse mortality or second tumors incidence. Patients who received WBRT experienced impairment in attentiveness and executive functions, whereas patients undergoing ASCT experienced improvement in these functions as well as in memory and quality of life.